Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma
Hematological Oncology · 2025
DOI: 10.1002/hon.70143 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Hematological Oncology, 2025. Verfasst von Christian Rausch und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, LMU University Hospital, Munich, Germany. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Ki-1 Antigen, Hodgkin Disease, Lymphoma, T-Cell, Peripheral. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Millenium Pharmaceuticals Inc., Takeda Pharmaceuticals International.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Patients with Hodgkin lymphoma (HL) or peripheral T‐cell lymphoma (PTCL) who relapse after high‐dose chemotherapy (HDCT) have a dismal prognosis. Brentuximab‐vedotin (BV) is a CD30‐targeting antibody‐drug‐conjugate (ADC) used in first‐line‐, salvage‐, and maintenance‐therapy of HL, as well as first‐line‐ and salvage‐therapy of PTCL. In phase I of this trial, we could show that BV can safely be added to BeEAM‐HDCT (bendamustine, etoposide, cytarabine and melphalan). Here, we report the randomized phase II part of the trial comparing BV‐BeEAM to BeEAM alone (ClinicalTrials.gov: NCT03187210). Primary endpoint was 1‐year disease‐free survival. Inclusion of 42 patients was planned but the study was terminated early, after a futility analysis showed lack of benefit. Twenty‐five patients (HL: 11, PTCL: 14) who were planned to undergo HDCT were included. Median age was 60 years. Patients had a median of two prior therapies, and 11 were previously exposed to BV. Patients in the standard‐arm had higher disease stage and (PTCL only) higher IPI. Duration of hospitalization, recovery of neutrophils/platelets, and infections were not significantly different between arms. No treatment related death occurred. However, two patients in the BV‐arm developed grade 3 pneumonitis. After 22 months median follow‐up, overall response‐rate, complete remission‐rate, disease‐free survival and overall survival did not differ between groups. Pre‐planned subgroup‐analyses (HL‐only, PTCL‐only, only those achieving CR) did not show benefit in any subgroup. In conclusion, adding BV to BeEAM does not improve outcomes after HDCT, and may increase pulmonary toxicity. Frequent prior exposure to BV may have limited the potential benefit of the combination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine III, LMU University Hospital, Munich, Germany.
- Department of Hematology and Central Hematological Laboratory, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.
- Department of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.
- Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
ORCID-Profile: Christian Rausch
Förderung
- Millenium Pharmaceuticals Inc.
- Takeda Pharmaceuticals International
Zitieren
APA
Rausch, C., Bacher, U., Rabaglio, M., Vorburger, C., Klingenberg, A., Banz, Y., Daskalakis, M., & Pabst, T. (2025). Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70143
Vancouver
Rausch C, Bacher U, Rabaglio M, Vorburger C, Klingenberg A, Banz Y, et al. Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma. Hematological Oncology. 2025. doi:10.1002/hon.70143
BibTeX
@article{Rausch2025,
author = {Rausch, Christian and Bacher, Ulrike and Rabaglio, Manuela and Vorburger, Corinne and Klingenberg, Anke and Banz, Yara and Daskalakis, Michael and Pabst, Thomas},
title = {Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70143}
}
EUVIMED